文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

局部晚期伴精囊侵犯前列腺癌在线自适应MRI引导SBRT中局灶加量的模拟研究

Simulation of Focal Boosting in Online Adaptive MRI-Guided SBRT for Patients With Locally Advanced Prostate Cancer With Seminal Vesicle Involvement.
PubMed 文献 · Pract Radiat Oncol · 2024-11-06

本研究利用23例T1-T3a前列腺癌患者在1.5T MR-Linac上接受局灶加量SBRT的数据,以人工GTV模拟T3b肿瘤,评估在线自适应MRI引导下局灶加量的可行性与准确性,并分析分次内运动对GTV和CTV计划剂量的影响。结果显示MRI引导可确保T3b病变局灶加量的高准确性,但由于GTV位置不利,相比T1-T3a患者可实现的加量剂量较低。

要点

  • 在23例T1-T3a患者数据中以人工GTV模拟T3b肿瘤,评估在线自适应MRI引导SBRT局灶加量。
  • 计划处方为CTV 35 Gy、GTV等毒性局灶加量至50 Gy。
  • 人工T3b肿瘤GTV的D98%ACC计划中位41.1 Gy,低于T1-T3a肿瘤的43.0 Gy。

核心结论

  • MRI引导可确保T3b病变患者局灶加量的高准确性。
  • 由于GTV位置不利,相比T1-T3a前列腺癌患者,可实现的加量剂量较低。

研究设计与样本

  • 研究使用23例接受局灶加量SBRT的T1-T3a前列腺癌患者在1.5T MR-Linac上的数据。
  • 由一名放射肿瘤科医生将临床GTV替换为代表T3b肿瘤的人工GTV。
  • 对每次用于每日自适应的MRI(MRIadapt)使用自适应轮廓自动生成治疗计划(Df1-5)。
  • 计划给予CTV 35 Gy,并对GTV进行等毒性局灶加量至50 Gy。
  • 每分次额外采集MRI(MRIduring)以评估分次内运动,并通过形变配准进行所有分次的剂量累积(DACC,计划)。

主要发现

  • 人工T3b肿瘤计划中GTV的D98%ACC(计划)中位数(第10-90百分位)为41.1 Gy(40.1-43.0 Gy),T1-T3a肿瘤计划为43.0 Gy(40.4-47.2 Gy)。
  • 考虑分次内运动后,人工GTV计划中GTV的D98%ACC(递送)为41.0 Gy(39.3-42.6 Gy),临床GTV计划为42.5 Gy(40.0-46.6 Gy)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the feasibility and accuracy of focal boosting in online adaptive MRI-guided stereotactic body radiation therapy (SBRT) for patients with prostate cancer (PCa) with seminal vesicle invasion (T3b) by analyzing the impact of intrafraction motion on the dose planned for the gross tumor volume (GTV) and clinical target volume (CTV). METHODS AND MATERIALS: Data from 23 patients with T1-T3a PCa who received focal boosting SBRT on a 1.5T MR-Linac was used. A radiation oncologist replaced clinical GTVs with artificial GTVs representative for T3b tumor(s). For each MRI used for daily adaptation (MRIadapt), an automated treatment plan was generated (Df1-5) using the adapted contours. Patients were planned to receive 35 Gy to the CTV, with an isotoxic focal boost to the GTV up to 50 Gy. During each fraction, an additional MRI was acquired to assess intrafraction motion (MRIduring). Dose accumulation of all fractions was performed by deformable registration of MRIadapt, f2-5 to MRIadapt, f1 (DACC, planned). The Df1-5 were projected to their corresponding MRIduring, which were used to reconstruct DACC, delivered, likewise. Our results were compared to patients with tumor(s) without seminal vesicle invasion (T1-T3a). RESULTS: The median (10th-90th percentile) D98%ACC, planned to the GTV, which correlates most strongly with outcome, was 41.1 Gy (40.1-43.0 Gy) in the plans for patients with artificial T3b tumors, compared to 43.0 Gy (40.4-47.2 Gy) in the plans for patients with T1-T3a tumors. The D98%ACC, delivered to the GTV, taking into account intrafraction motion, was 41.0 Gy (39.3-42.6 Gy) and 42.5 Gy (40.0-46.6 Gy) in the plans for the artificial and clinical GTVs, respectively. CONCLUSIONS: MRI-guidance can ensure high accuracy of focal boosting in patients with T3b disease. Because of the unfavorable location of the GTV, a lower boost dose was feasible compared to patients with T1-T3a PCa.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Dassen MG, Neijndorff B, Betgen A, et al. Simulation of Focal Boosting in Online Adaptive MRI-Guided SBRT for Patients With Locally Advanced Prostate Cancer With Seminal Vesicle Involvement. Pract Radiat Oncol. 2024. PMID: 39510409. doi:10.1016/j.prro.2024.10.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。